Our findings present a basis for the clinical assessment of combined targeting of oncogene-driven glycometabolism (such as inhibition of c-Myc, HIF-1α, and EGFR) and Glut1 in patients with resistance TKIs of NSCLC. This evidence concerns the gene SLC2A1 and non-small cell lung carcinoma.